Thestocktraderhubzee
Posted - 6 days ago
$ELVN Baird Maintains Outperform on Enliven Therapeutics, Raises Price Target to $40
ChessGM
Posted - 2 weeks ago
$ELVN Heads up alert! Only one day until Upcoming earnings on Friday, 11/8/2024 for $ELVN Bullish (8.3) Enliven Therapeutics (ELVN) is currently positioned favorably within the pharmaceutical sector, particularly due to the promising developments surrounding its drug ELVN-001 for chronic myeloid leukemia (CML). Analyst Salim Syed from Mizuho Americas identifies ELVN as a robust investment opportunity, projecting the potential for the drug to generate revenues between $1 billion to $2 billion in a $14 billion global market. The stock is presently trading at a market cap of approximately $1 billion, indicating a significant upside potential when compared to projected revenue streams. Key metrics reveal that ELVN-001 has reported a cumulative major molecular response (MMR) rate of 44% in its Phase I trials, with no dose reductions needed, suggesting a favorable safety profile and efficacy. Given that the company is in the early stages of drug development, with the potential market entry of ELVN-001 anticipated around 2028, investors may find a compelling risk-reward dynamic, especially considering the historical performance of similar therapeutics. Comparing ELVN to industry peers, it appears to be valued attractively, especially if it can achieve the anticipated revenue targets. As for upcoming earnings reports, expectations are building around Enliven Therapeutics, particularly in light of the positive Phase I trial data for ELVN-001. Analysts are bullish on the stock, factoring in the encouraging clinical outcomes that could drive significant future revenues. The historical performance of the company, along with the consensus estimates from analysts, suggest that there is a strong belief in ELVN's potential to outperform in the coming quarters. Investor sentiment is likely to hinge on continued positive updates regarding the clinical trials, as well as broader market trends in oncology therapeutics. The anticipated earnings report could serve as a crucial catalyst, with analysts projecting robust growth potential, which would further solidify ELVN's standing in the competitive biotech landscape. - Funds were net buyers of $ELVN during the previous reporting quarter. - Top 5 funds with large holdings in $ELVN: * OrbiMed Advisors LLC $186MM. New position. CGMFundRank: 55%, Fund Website: www.orbimed.com * RA Capital Management LLC $50MM. New position. CGMFundRank: 61%, Fund Website: www.racap.com * Adage Capital P $20MM. New position. CGMFundRank: 87%, Fund Website: www.adagecapital.com * Soleus Capital $18MM. New position. CGMFundRank: 57% * Boxer Capital LLC $16MM. New position. CGMFundRank: 74%, Fund Website: www.boxercap.com - Last 10 days performance: 3% - Last 30 days performance: 5% - Last 90 days performance: 39% Follow ChessGM on stocktwits.com to get timely earnings alerts. Not a financial advice. Not a trading signal.
Doozio
Posted - 2 weeks ago
list of $xbi stonks ready to get $spry ? it’s moar then a $thrd of them which is much moar then $elvn during 🧠⏰♾️
IN0V8
Posted - 10/31/24
$ELVN Jonestrading initiates coverage with buy rating; PT $36
insiderbuyingselling
Posted - 10/30/24
$ELVN new insider selling: 6250 shares. http://insiderbuyingselling.com/?t=ELVN
Fugazi_
Posted - 10/23/24
$ELVN insiders selling huh
insiderbuyingselling
Posted - 10/23/24
$ELVN new insider selling: 816 shares. http://insiderbuyingselling.com/?t=ELVN
insiderbuyingselling
Posted - 10/23/24
$ELVN new insider selling: 924 shares. http://insiderbuyingselling.com/?t=ELVN
insiderbuyingselling
Posted - 10/22/24
$ELVN new insider selling: 814 shares. http://insiderbuyingselling.com/?t=ELVN
RamenLives
Posted - 10/22/24
$ANNX $ELVN Opened positions
insiderbuyingselling
Posted - 1 month ago
$ELVN new insider selling: 1270 shares. http://insiderbuyingselling.com/?t=ELVN
Datastep
Posted - 1 month ago
$ELVN I bought this two weeks ago as a starter position. It‘s been going up since then. With the strength in share price, it seems to be one to keep an eye on. Plus, the stocks i I usually don’t buy a lot of shares in, go up the most
insiderbuyingselling
Posted - 1 month ago
$ELVN new insider selling: 29977 shares. http://insiderbuyingselling.com/?t=ELVN
insiderbuyingselling
Posted - 1 month ago
$ELVN new insider selling: 10229 shares. http://insiderbuyingselling.com/?t=ELVN
insiderbuyingselling
Posted - 1 month ago
$ELVN new insider selling: 2825 shares. http://insiderbuyingselling.com/?t=ELVN
Doozio
Posted - 1 month ago
Gonna count to 10! On YO mark get set $elvn !!
Doozio
Posted - 1 month ago
Aren’t YO $glad da FUTUre of 🧠⏰ NOW has moar then $elvn huckleberries at da $$$$ patterns during 🧠⏰♾️
Doozio
Posted - 1 month ago
Da FUTUre of 🧠⏰ NOW wants moar FOUR $elvn during 🧠⏰♾️
Doozio
Posted - 1 month ago
$ELVN bahhht wen do they start CHSN???
insiderbuyingselling
Posted - 1 month ago
$ELVN new insider selling: 518 shares. http://insiderbuyingselling.com/?t=ELVN
insiderbuyingselling
Posted - 1 month ago
$ELVN new insider selling: 526 shares. http://insiderbuyingselling.com/?t=ELVN
insiderbuyingselling
Posted - 1 month ago
$ELVN new insider selling: 521 shares. http://insiderbuyingselling.com/?t=ELVN
insiderbuyingselling
Posted - 1 month ago
$ELVN new insider selling: 6250 shares. http://insiderbuyingselling.com/?t=ELVN
fallondpicks
Posted - 09/30/24
46 #stockbreakouts $BALT, $BWAY (gap), $ELVN, $SCE/PJ. This is one of the worst set of breakout stocks given the high number qualifying for scan conditions. Seven sub-$1, four $1-2.
Doozio
Posted - 09/30/24
$ELVN da FUTUre of 🧠⏰ is NOW during 🧠⏰♾️
themacromindset
Posted - 09/30/24
$ELVN $ELVN Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia
RockyTSTH
Posted - 2 months ago
$ELVN Enliven Therapeutics shares are trading higher after the company provided more details regarding the presentation of its updated ELVN-001 Phase1a data of ESH-iCML at the 26th annual John Goldman Conference on CML.
Stock_Titan
Posted - 2 months ago
$ELVN Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML
https://www.stocktitan.net/news/ELVN/enliven-therapeutics-announces-details-regarding-the-presentation-of-zyeo2cbncnlb.html